Bauer takes role of president at Chemwerth

Formerly with Sandoz

Jeffrey Bauer has taken over as president of ChemWerth, a US supplier of active pharmaceutical ingredients for generic medicines.

Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.

Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.

ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like

Pharmaceutical
OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT has launched two IVDR-certified prenatal FISH probe kits as it begins transitioning its full CytoCell portfolio ahead of the EU’s 2028 Class C deadline
Pharmaceutical
CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
The peptide pipeline is changing shape: is manufacturing keeping pace?

The peptide pipeline is changing shape: is manufacturing keeping pace?

GLP-1 demand has reshaped industrial peptide production, but tomorrow’s complex pipeline will reward the CDMOs that incorporate flexibility, quality and resilient supply chains
Ingredients
Brenntag launches BYPHAR biopharma raw material portfolio spanning R&D through commercial GMP manufacture

Brenntag launches BYPHAR biopharma raw material portfolio spanning R&D through commercial GMP manufacture

The three-tier range — covering non-GMP research materials through LBLE critical-grade excipients — consolidates regulatory documentation, global supply reliability and technical support for mAbs, CGT, ADCs and nucleic acid production under one brand
Packaging
Designing the future of pharma packaging – in Europe

Designing the future of pharma packaging – in Europe

Are you thinking about sustainable pharmaceutical packaging? ACG is committed to advancing sustainability in pharmaceutical packaging
Pharmaceutical
Reconstitutable powder filling system for global MedTech client

Reconstitutable powder filling system for global MedTech client

3P innovation's custom automation expertise enables customers to advance product and process innovation across diverse industries
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Subscribe now